125 related articles for article (PubMed ID: 11107151)
21. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression.
Kitanaka C; Kato K; Ijiri R; Sakurada K; Tomiyama A; Noguchi K; Nagashima Y; Nakagawara A; Momoi T; Toyoda Y; Kigasawa H; Nishi T; Shirouzu M; Yokoyama S; Tanaka Y; Kuchino Y
J Natl Cancer Inst; 2002 Mar; 94(5):358-68. PubMed ID: 11880474
[TBL] [Abstract][Full Text] [Related]
22. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
23. The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor.
Nagata T; Takahashi Y; Asai S; Ishii Y; Mugishima H; Suzuki T; Chin M; Harada K; Koshinaga S; Ishikawa K
J Surg Res; 2000 Aug; 92(2):267-75. PubMed ID: 10896833
[TBL] [Abstract][Full Text] [Related]
24. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
[TBL] [Abstract][Full Text] [Related]
25. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
26. Gene expression of TRK neurotrophin receptors in advanced neuroblastomas in Singapore--a pilot study.
Fung W; Hasan MY; Loh AH; Chua JH; Yong MH; Knight L; Hwang WS; Chan MY; Seow WT; Jacobsen AS; Chui CH
Pediatr Hematol Oncol; 2011 Oct; 28(7):571-8. PubMed ID: 21728718
[TBL] [Abstract][Full Text] [Related]
27. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
Suita S
J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
[TBL] [Abstract][Full Text] [Related]
28. Biological aspects of neuroblastomas identified by mass screening in Quebec.
Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
[TBL] [Abstract][Full Text] [Related]
29. A neuroblastoma cell line derived from a case detected through a mass screening system in Japan: a case report including the biologic and phenotypic characteristics of the cell line.
Hiraiwa H; Hamazaki M; Takata A; Kikuchi H; Hata J
Cancer; 1997 May; 79(10):2036-44. PubMed ID: 9149033
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma.
Eggert A; Ikegaki N; Liu XG; Brodeur GM
Klin Padiatr; 2000; 212(4):200-5. PubMed ID: 10994551
[TBL] [Abstract][Full Text] [Related]
31. Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis.
Kato C; Miyazaki K; Nakagawa A; Ohira M; Nakamura Y; Ozaki T; Imai T; Nakagawara A
Int J Cancer; 2004 Nov; 112(3):365-75. PubMed ID: 15382060
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of favorable and unfavorable neuroblastomas.
Hiyama E; Hiyama K; Yamaoka H; Sueda T; Reynolds CP; Yokoyama T
Pediatr Surg Int; 2004 Jan; 20(1):33-8. PubMed ID: 14691637
[TBL] [Abstract][Full Text] [Related]
33. Is there a future for neuroblastoma mass screening?
Bessho F
Med Pediatr Oncol; 1998 Aug; 31(2):106-10. PubMed ID: 9680937
[TBL] [Abstract][Full Text] [Related]
34. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
35. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
36. Persistence and possible progression of a pelvic neuroblastoma detected by mass screening during 19 months.
Bernstein ML; Azouz EM; Woods W; Tuchman M; Renaud L; Lemieux B
Am J Pediatr Hematol Oncol; 1994 May; 16(2):164-6. PubMed ID: 8166370
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathology of human neuroblastomas.
Brodeur GM
Semin Diagn Pathol; 1994 May; 11(2):118-25. PubMed ID: 7809505
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification.
Hiyama E; Yamaoka H; Kondo S; Yoneda A; Tajiri T; Fukuzawa M; Sugiyama M; Hayashi Y; Sasaki F; Ohtaki M
Pediatr Surg Int; 2007 Nov; 23(11):1051-8. PubMed ID: 17701415
[TBL] [Abstract][Full Text] [Related]
39. Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.
Sawada T; Nagahara N; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Okawa H; Tsunoda A; Sakurai M
Acta Paediatr Jpn; 1990 Dec; 32(6):725-33. PubMed ID: 2082676
[TBL] [Abstract][Full Text] [Related]
40. Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.
Tajiri T; Souzaki R; Kinoshita Y; Tanaka S; Koga Y; Suminoe A; Matsuzaki A; Hara T; Taguchi T
J Pediatr Surg; 2009 Dec; 44(12):2253-7. PubMed ID: 20006005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
